66,188 Shares in Personalis, Inc. $PSNL Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG acquired 66,188 Personalis shares in the second quarter, valued at approximately $887,000; institutional investors and hedge funds collectively own 61.91% of PSNL.
• Personalis reported quarterly revenue of $22.36 million, exceeding estimates, but its $0.30 loss per share missed expectations. The company posted a negative net margin of 153.84%.
• Analyst sentiment remains mixed, with an overall “Hold” rating and a consensus price target of $14.54, while company insiders sold 296,233 shares worth about $4.05 million over the past 90 days.

Deutsche Bank AG bought a new position in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 66,188 shares of the company's stock, valued at approximately $887,000. Deutsche Bank AG owned 0.06% of Personalis as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PSNL. Royal Bank of Canada raised its position in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after purchasing an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock worth $269,000 after buying an additional 33,044 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after buying an additional 101,706 shares during the period. Focus Partners Wealth acquired a new position in Personalis in the 1st quarter valued at $47,000. Finally, JPMorgan Chase & Co. grew its stake in Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company's stock valued at $193,000 after buying an additional 24,621 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Stock Down 1.7%

PSNL stock opened at $16.78 on Tuesday. Personalis, Inc. has a twelve month low of $4.65 and a twelve month high of $18.89. The company has a market cap of $1.76 billion, a PE ratio of -15.39 and a beta of 2.27. The business's 50-day simple moving average is $14.13 and its 200 day simple moving average is $10.05.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. On average, equities research analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company's stock, valued at $3,558,668.88. The trade was a 29.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company's stock, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 296,233 shares of company stock valued at $4,048,636 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PSNL. Morgan Stanley boosted their target price on shares of Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. Wall Street Zen downgraded Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Personalis in a research note on Friday, July 17th. BTIG Research boosted their price objective on Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a research report on Monday, July 20th. Finally, Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 target price on the stock. in a report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $14.54.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source